Pfizer Reports ₹722.43 Cr Profit for Full Year on 10.35% Revenue Growth

Key Financials Announced

Pfizer Ltd announced its financial results for the fiscal year and quarter ending March 31, 2026.

For the full fiscal year, revenue grew 10.35% to ₹2,707.60 crore, with annual net profit at ₹722.43 crore. This compares to ₹767.60 crore last year, with the difference largely due to a ₹172.81 crore one-time gain from property sales in the prior year that did not repeat.

For the quarter, net profit fell to ₹199.82 crore, affected by ₹49.16 crore in exceptional charges. These charges included ₹41.73 crore for personnel separation costs tied to a supply agreement with Cipla Limited, and ₹7.43 crore for new labor code provisions. Despite the quarterly profit dip, total income for the period rose 5.26% year-on-year to ₹669.95 crore.

What the Results Show

The results show Pfizer's core operations are delivering steady revenue growth.

Year-on-year profit comparisons are significantly impacted by one-off items, including current year exceptional charges and last year's large gain from asset sales.

Financially, the company remains strong, with substantial cash reserves and minimal debt.

Background on Costs

Recent strategic initiatives, like the manufacturing and supply agreement with Cipla Limited, led to temporary exceptional costs.

These costs are related to personnel adjustments during the transition phase of this major agreement.

Shareholder Returns and Financial Strength

Shareholders can expect substantial returns, as the Board recommended a final dividend of ₹75 per share (750%).

The company's balance sheet remains exceptionally strong, with total equity at ₹4,202.90 crore and borrowings at a negligible ₹2.50 crore.

Statutory auditors provided a clean audit opinion, assuring the reliability of financial reporting.

Key Considerations for Investors

Investors should watch the financial impact of the exceptional charges, especially those related to the Cipla agreement.

The year-on-year profit comparison will continue to be affected by the base effect from last year's large land sale gain.

Comparison with Peers

Pfizer Ltd's 10.35% annual revenue growth for the year ended March 31, 2026, is a solid performance. For comparison, Abbott India reported FY25 revenue of ₹5,483 crore, and Cipla reported FY25 revenue of ₹29,069 crore, showing a dynamic sector.

While Pfizer's annual profit decreased due to one-off items, its core revenue generation remains competitive in the Indian pharmaceutical sector.

Key Financial Metrics

• Standalone Total Income: ₹669.95 crore (Quarter ended March 31, 2026)
• Standalone Net Profit: ₹199.82 crore (Quarter ended March 31, 2026)
• Quarterly YoY Revenue Growth: 5.26% (Quarter ended March 31, 2026 vs Quarter ended March 31, 2025)
• Quarterly EPS: ₹43.68 (Quarter ended March 31, 2026)
• Standalone Total Income: ₹2,707.60 crore (Year ended March 31, 2026)
• Standalone Net Profit: ₹722.43 crore (Year ended March 31, 2026)
• Annual YoY Revenue Growth: 10.35% (Year ended March 31, 2026 vs Year ended March 31, 2025)
• Annual EPS: ₹157.92 (Year ended March 31, 2026)
• Bank Balances (excluding cash equivalents): ₹3,008.10 crore (As of March 31, 2026)
• Borrowings: ₹2.50 crore (As of March 31, 2026)
• Total Equity: ₹4,202.90 crore (As of March 31, 2026)
• Recommended Final Dividend: ₹75 per share (750%) (Year ended March 31, 2026)
• Net Exceptional Charges: ₹49.16 crore (Year ended March 31, 2026)
• Prior Year Land & Building Sale Gain: ₹172.81 crore (Year ended March 31, 2025)

Looking Ahead

Successful integration and financial outcomes of the Cipla manufacturing and supply agreement are key.

Sustaining revenue growth momentum into the next fiscal year will be important.

Monitor management's comments on future strategies and margin outlook.

Track the use of strong cash reserves and the company's dividend policies.